NATURAL PRODUCT FROM GELATINOUS ZOOPLANKTON

这个项目的目标是系统地探索凝胶状的 浮游动物的抗肿瘤和其他生物活性。 以下 将收集无脊椎动物群：刺胞动物（水螅水母，水螅， scyphomedusae，管水母类），栉水母类，软体动物（翼足类，异足类， 裸鳃类）和尾索动物（被囊类、珊瑚虫、火体动物）。 一期 将集中收集150-200个系统计划总数的10% 的成本效益，并评估了几个收集和 收集方法（水桶、拖网和SCUBA）。 样品将 提取并针对一组5-6种人肿瘤细胞系进行筛选。 活性提取物将根据生物学特性进一步分级。 活性和化学描述。 第二阶段将继续这项工作， 国家癌症研究所将有机会筛选这些藏品。 是 预计新的化学实体，重要的药物 活动，将被描述和专利;他们将被授权给 政府或制药公司的发展。 对凝胶状浮游动物的评估为研究海洋生物提供了新的机会。 药物发现。 只有少数物种被评估，因为 认为收集和再收集浮游动物的技术困难 以千克计。 这些浮游生物很可能是 生物活性代谢物，因为它们的底栖（海底生活）亲属 产生了许多具有生物活性的代谢产物。

The goal of this project is to systematically explore the gelatinous zooplankton for antitumor and other biological activities. The following invertebrate groups will be collected: Cnidaria (hydromedusae, hydroids, scyphomedusae, siphonophores), Ctenophora, Mollusca (pteropods, heteropods, nudibranchs), and Urochordata (tunicates, doliolids, pyrosomes). Phase I will concentrate on collecting 10% of a systematic program total of 150-200 species and on evaluating the cost-effectiveness of several collection and recollection methods (bucket, trawl, and SCUBA). Samples will be extracted and screened against a panel of 5-6 human tumor cell lines. Active extracts will be further fractionated according to biological activity, and described chemically. Phase II will continue this work and the NCI will be given the opportunity to screen the collection. It is expected that new chemical entities, with important pharmaceutical activities, will be described and patented; they will be licensed to the government or pharmaceutical companies for development. The evaluation of gelatinous zooplankton represents a new opportunity for drug discovery. Only a few species have been evaluated due to the perceived technical difficulty of collecting and recollecting zooplankton in kilogram quantities. These planktonic species are likely sources of bioactive metabolites since their benthic (bottom-living) relatives have yielded many bioactive metabolites.